Greenville, North Carolina, August 19, 2026
Arcato Laboratories, Inc. has announced positive topline results from its first-in-human Phase 1 clinical trial of ARC-001 Gel, an investigational sustained-release local analgesic being developed to manage pain following third molar, or wisdom tooth, extraction surgery. At the same time, the company announced the closing of its fully subscribed first financing round, providing additional resources to advance development of the novel pain-management candidate. The Phase 1 study achieved its primary safety endpoint, while exploratory efficacy analyses indicated that a single administration of ARC-001 Gel may reduce postoperative pain during the first 24 hours and potentially provide analgesic effects for up to one week.
ARC-001 Gel Demonstrates Phase 1 Safety
ARC-001 Gel is a proprietary, single-dose sustained-release formulation combining three established, non-addictive local anesthetics: benzocaine, lidocaine, and bupivacaine. The formulation is designed for direct administration into the tooth socket immediately following surgical extraction. Unlike conventional injectable pain treatments, the investigational product is delivered as a gel without an injection or needle, potentially offering an alternative approach to postoperative local pain management. According to Arcato, the pharmacokinetic profile of the formulation supports the potential for prolonged local analgesia following a single administration. In the Phase 1 study, the primary endpoint focused on safety, and the company reported that this endpoint was successfully achieved. The findings support continued development of ARC-001 Gel and provide a basis for advancing the program toward Phase 2 and Phase 3 clinical studies.
Exploratory Findings Point to Prolonged Pain Relief
In addition to the positive safety findings, exploratory efficacy analyses provided early evidence of potential analgesic activity. Arcato reported that patients receiving ARC-001 Gel experienced reduced postoperative pain during the first 24 hours, while additional analyses suggested that the effect could potentially continue for as long as seven days following a single dose. The company also reported an exploratory finding related to opioid use: patients receiving placebo self-reported a need for opioids approximately twice as often as patients who received ARC-001 Gel to manage postoperative pain. These findings remain exploratory and will require confirmation in larger, appropriately designed clinical trials. Nevertheless, the results highlight the potential of a sustained-release, non-addictive local formulation to address pain following dental and oral surgery. With more than 3 million third molar procedures performed annually in the United States, Arcato believes there is a substantial clinical need for additional postoperative pain-management options that could help reduce reliance on opioid medications.
Advertisement
Financing Supports Further Clinical Development
Alongside the clinical update, Arcato Laboratories announced the closing of its first financing round, which was fully subscribed. The financing is expected to support the company’s continued development of ARC-001 Gel as it prepares for later-stage clinical evaluation. Arcato said it is actively engaged with the U.S. Food and Drug Administration (FDA) and is aligning its development strategy with the agency’s May 2026 draft guidance for non-opioid analgesics. The company’s approach focuses on developing a targeted treatment for postoperative oral pain using established anesthetic agents in a novel sustained-release formulation. The combination of Phase 1 safety data, preliminary efficacy observations, and new financing marks an important development milestone for the program. As Arcato moves toward Phase 2/3 development, future studies will be important for establishing the durability, efficacy, safety, and clinical utility of ARC-001 Gel in larger patient populations. If successful, the investigational therapy could provide dentists and oral surgeons with another option for managing acute postoperative pain while supporting efforts to reduce unnecessary opioid exposure.
Source: Arcato Laboratories press relese
